Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

被引：0
|
作者：
Chai, C. S. [1 ]
Liam, C. K. [2 ]
Pang, Y. K. [2 ]
Kow, K. S. [2 ]
Wong, C. K. [2 ]
Poh, M. E. [2 ]
Tan, J. L. [2 ]
机构：
[1] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Kota Samarahan, Malaysia
[2] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
470P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
    Midori Tanaka
    Hidenobu Ishii
    Hayato Moribuchi
    Yoshiko Naito
    Norikazu Matsuo
    Masayuki Nakamura
    Takaaki Tokito
    Koichi Azuma
    Kazuhiko Yamada
    Tomoaki Hoshino
    Investigational New Drugs, 2018, 36 : 715 - 717
  • [32] Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
    Widiasari, Ni Putu Ayu
    Rai, Ida Bagus Ngurah
    Jasminarti, Ida Ayu D. K.
    Sajinadiyasa, I. Gede Ketut
    Candrawati, Ni Wayan
    Arisanti, Ni Luh Putu Eka
    ROMANIAN JOURNAL OF INTERNAL MEDICINE, 2023, 61 (01) : 63 - 71
  • [33] Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma
    Castaneda-Zarraga, Anahi
    Rodriguez-Cid, Jeronimo Rafael
    Flores-Marinelarena, Rodrigo Rafael
    Trinidad-Bibiano, Hector
    Martinez-Herrera, Jose Fabian
    Sanchez-Rios, Carla Paola
    Fernandez-Garibay, Valeria Michelle
    Alatorre-Alexander, Jorge Arturo
    Martinez-Barrera, Luis
    Santillan-Doherty, Patricio Javier
    Vega-Memije, Maria Elisa
    THORACIC CANCER, 2020, 11 (11) : 3243 - 3251
  • [34] Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
    Xie, Yalin
    Su, Ning
    Zhou, Wei
    Lei, An
    Li, Xiang
    Li, Weiwei
    Huang, Zhan
    Cen, Wenchang
    Hu, Jinxing
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7517 - 7526
  • [35] Efficacy of Tyrosine Kinase Inhibitor for Non-adenocarcinoma NSCLC Patients With EGFR Mutation
    Cho, S. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S620 - S620
  • [36] Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
    Lee, Sang Hoon
    Kim, Eun Young
    Kim, Arum
    Chang, Yoon Soo
    CANCER BIOLOGY & THERAPY, 2020, 21 (08) : 741 - 748
  • [37] Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response
    Park, Ha Young
    Oh, Hyung Joo
    Kim, Ki-Hyun
    Kim, Tae-Ok
    Park, Cheol-Kyu
    Shin, Hong-Jun
    Lim, Jung-Hwan
    Kwon, Yong-Soo
    Oh, In-Jae
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    Choi, Yoo-Duk
    THORACIC CANCER, 2016, 7 (06) : 639 - 647
  • [38] Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
    Sun, Yan
    Yu, Xinmin
    Shi, Xun
    Hong, Wei
    Zhao, Jun
    Shi, Lei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [39] EGFR-TYROSINE KINASE INHIBITOR TREATMENT BEYOND PROGRESSION IN LONG-TERM RESPONDERS TO ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER: RELEVANCE OF EGFR MUTATION STATUS
    Faehling, M.
    Eckert, R.
    Kamp, T.
    Straeter, J.
    Ott, G.
    Spengler, W.
    ANNALS OF ONCOLOGY, 2012, 23 : 440 - 440
  • [40] Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
    Yan Sun
    Xinmin Yu
    Xun Shi
    Wei Hong
    Jun Zhao
    Lei Shi
    World Journal of Surgical Oncology, 12
12345